3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
93
Leukemia
70
Lymphoma
52
Leukemia, Myeloid, Acute
41
Burkitt Lymphoma
36
Myelodysplastic Syndromes
32
Lymphoma, Non-Hodgkin
27
Hodgkin Disease
27
Lymphoma, Mantle-Cell
24
Leukemia, Lymphocytic, Chronic, B-Cell
23
Recurrence
21
Lymphoma, Large B-Cell, Diffuse
21
Graft vs Host Disease
21
Lymphoma, Follicular
19
Congenital Abnormalities
18
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
17
Multiple Myeloma
17
Leukemia, Myeloid, Accelerated Phase
16
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
16
Myeloproliferative Disorders
15
Leukemia, Myelomonocytic, Chronic
15
Blast Crisis
15
Lymphoma, B-Cell, Marginal Zone
14
Leukemia, Myeloid, Chronic-Phase
13
Lymphoma, Large-Cell, Immunoblastic
12
Hematologic Neoplasms
12
Primary Myelofibrosis
11
Lymphoma, Large-Cell, Anaplastic
11
Breast Neoplasms
11
Neoplasms, Plasma Cell
10
Interventions
Methotrexate
1
Brentuximab Vedotin
1
Bexarotene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphoma, Primary Cutaneous Anaplastic Large Cell
×
Methotrexate
×
Clear all
NCT01578499
2021-01-05
ALCANZA
Takeda
Phase 3
Completed
131 enrolled
24 charts